GlassScriptPhysician profile
Cary E Feibleman
NPI 1740207737
$6,961.23
in general payments reported to CMS, 2019-2025
23 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $498 · 2021: $462 · 2022: $240 · 2023: $706 · 2024: $2,007 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,885 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,884.96 |
| Education | $362.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,397.30 | 2020-2025 | Tremfya |
| Epi Health, LLC | $1,186.36 | 2019 | |
| Abbvie INC. | $564.45 | 2019-2025 | |
| Ucb, INC. | $532.14 | 2019-2025 | Cimzia, Bimzelx |
| Leo Pharma INC. | $469.80 | 2024-2025 | Adbry |
| Incyte Corporation | $350.96 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $310.95 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $302.50 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $247.38 | 2019-2025 | |
| Genzyme Corporation | $224.95 | 2020-2025 | |
| Almirall LLC | $197.80 | 2024 | Klisyri |
| Amgen INC. | $197.43 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $186.60 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $160.17 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $150.18 | 2023-2025 | Dupixent, Libtayo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $149.68 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $123.73 | 2020-2024 | Ilumya |
| Arcutis Biotherapeutics, INC. | $61.98 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $57.31 | 2023 | Vtama |
| Biofrontera INC. | $26.33 | 2025 | |
| Organon LLC | $24.91 | 2025 | Vtama |
| Genentech USA, INC. | $19.89 | 2021 | |
| Galderma Laboratories, L.P. | $18.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Feibleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.